ArticleHaematologica2020

Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma.

Max S Topp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.